Arkansas Development Finance Authority; General Obligation Jan 13

  • ID: 2383732
  • January 2013
  • Region: Arkansas
  • Standard & Poors
1 of 3

Standard & Poor's Ratings Services affirmed its 'AA' issuer credit rating (ICR) on Arkansas Development Finance Authority (ADFA). The outlook is stable. The rating reflects our view of the following strengths of the authority: The strong trends in financial performance; The very strong quality and low risk profile of the authority's asset base; The experienced management team; and The ongoing ability to meet its legislative mandate, and maintenance of a strong relationship with the state government. These strengths are partly offset by our opinion of the following weakness of the authority: The declining investment income. ADFA is the primary bond issuing authority in Arkansas. In addition to issuing affordable housing debt, the authority issues debt for economic development programs and...

Companies mentioned in this report are:
- Arkansas Dev Fin Auth

Action: Affirmed

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research Type: Full Analysis

Note: Product cover images may vary from those shown
2 of 3

- Arkansas Dev Fin Auth

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown


  • Quick Help: This Credit Rating Report will be emailed to you.


If you have a more general question about our products please try our



Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer, Inc.